{
  "id": "PK_CYP2C19_INHIB_CLOPIDOGREL",
  "name": "CYP2C19 inhibition can reduce activation of clopidogrel",
  "domain": "PK",
  "severity": "major",
  "rule_class": "adjust_monitor",
  "tags": ["activation_decrease"],
  "actions": [
    "Consider alternative antiplatelet therapy not dependent on CYP2C19 activation (educational).",
    "Be aware this interaction reduces efficacy rather than increasing toxicity."
  ],
  "logic": {
    "enzyme": {
      "id": "CYP2C19",
      "A_role": "substrate",
      "B_role": "inhibitor"
    },
    "rationale": [
      "Clopidogrel is a prodrug requiring CYP2C19-mediated activation.",
      "Reduced activation can lower antiplatelet effect."
    ]
  },
  "explanation_template": "{B_name} inhibits CYP2C19 and {A_name} relies on CYP2C19 for activation. This can reduce formation of the active metabolite and decrease antiplatelet effect.",
  "references": [
    {
      "source": "Educational note",
      "citation": "Prodrug pattern: pathway inhibition can reduce therapeutic activation."
    }
  ]
}
